Loading...
The University of Chicago Header Logo
Keywords
Last Name
Institution

Connection

Jonathan Chung to Piperazines

This is a "connection" page, showing publications Jonathan Chung has written about Piperazines.

 
Connection Strength
 
 
 
0.882
 
  1. Necchi A, Raggi D, Giannatempo P, Alessi A, Serafini G, Colecchia M, Ali SM, Chung JH. Exceptional response to olaparib in BRCA2-altered urothelial carcinoma after PD-L1 inhibitor and chemotherapy failure. Eur J Cancer. 2018 06; 96:128-130.
    View in: PubMed
    Score: 0.670
  2. Gornstein EL, Sandefur S, Chung JH, Gay LM, Holmes O, Erlich RL, Soman S, Martin LK, Rose AV, Stephens PJ, Ross JS, Miller VA, Ali SM, Blau S. BRCA2 Reversion Mutation Associated With Acquired Resistance to Olaparib in Estrogen Receptor-positive Breast Cancer Detected by Genomic Profiling of Tissue and Liquid Biopsy. Clin Breast Cancer. 2018 04; 18(2):184-188.
    View in: PubMed
    Score: 0.164
  3. Mao P, Cohen O, Kowalski KJ, Kusiel JG, Buendia-Buendia JE, Cuoco MS, Exman P, Wander SA, Waks AG, Nayar U, Chung J, Freeman S, Rozenblatt-Rosen O, Miller VA, Piccioni F, Root DE, Regev A, Winer EP, Lin NU, Wagle N. Acquired FGFR and FGF Alterations Confer Resistance to Estrogen Receptor (ER) Targeted Therapy in ER+ Metastatic Breast Cancer. Clin Cancer Res. 2020 11 15; 26(22):5974-5989.
    View in: PubMed
    Score: 0.049
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.